Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current Stimulation
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Treatment group differences in change from Baseline to 1-week Post-Treatment on COWAT Phonemic Fluency
研究概览
简要总结
The purpose of this research study is to examine the effects of transcranial Direct Current Stimulation (tDCS) on verbal retrieval and cognition and sensorimotor control and to determine if tDCS can be used as a way to improve retrieval, sensory, and motor abilities in individuals with Parkinson's disease (PD).
详细描述
Objective
Based on models of semantic memory retrieval developed, under which the pre-supplementary motor area (preSMA) of the dorsomedial frontal lobes play an important role, the study will examine the treatment of cognitive deficits in PD with HD tDCS applied to the preSMA to improve function in neural circuits supporting verbal retrieval. In addition, as the preSMA is implicated in motor planning and sequencing, the study also will explore whether HD tDCS applied to the preSMA will have an effect on speech and gait.
Specific Aims:
- Examine the therapeutic effects on verbal retrieval function by modulating the preSMA using HD tDCS.
- Examine the therapeutic effects on speech production and processing by modulating the preSMA using HD tDCS
- Examine the therapeutic effects on gait and balance by modulating the preSMA using HD tDCS
Hypotheses:
- : Active HD tDCS (1 ma anodal HD tDCS to the preSMA compared to sham) will improve verbal fluency (i.e, phonemic and category fluency on Controlled Word Association Test) as primary outcome measures.
- : Active HD tDCS (1 ma anodal HD tDCS to the preSMA compared to sham) will improve speech sequencing.
- : Active HD tDCS (1 ma anodal HD tDCS to the preSMA compared to sham) will improve general motor sequencing
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Participants, assessors, and technicians interacting with participants will be blind to assigned conditions. The software for the transcranial direct current system allows for maintaining blinds when uploading and running protocols.
入排标准
- 年龄范围
- 50 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with PD having a verbal fluency deficit based on neuropsychological test (T-score < 40 or a T-score <-1.0 SD below the average T-score): Semantic Object Retrieval Test (SORT), COWAT (both letter and category fluency), Boston Naming Test (BNT), Rey Auditory Verbal Learning Test (RAVLT)
- •50 - 90 years old
- •Capable of understanding and signing an informed consent (able to answer consent comprehension questions)
- •Fluent in speaking and reading English
排除标准
- •A potentially study-confounding, tDCS-contraindicated, or EEG-contraindicated psychological, neuropsychiatric, neurological, or other medical issues:
- •Montreal Cognitve Assessment (MOCA) score <23, unless an accompanying study partner/caregiver is with them and we can obtain the written consent of both the participant and the participant's accompanying study partner/caregiver (i.e., the participant's spouse, adult child, parent, or adult sibling);
- •history of seizures;
- •unexplained episodes of loss of consciousness (as these may be related to brain alterations or epilepsy);
- •suffering from severe or frequent headaches;
- •unstable or uncontrolled neuropsychiatric illness;
- •severe traumatic brain injury (based on the Ohio State TBI Identification; Method);
- •brain tumor; stroke; present drug abuse/misuse;
- •brain tumor;
- •serious or life-threatening diseases, including congestive heart failure, chronic obstructive pulmonary disease, or active malignancy;
- •Huntington's disease;
- •cranial implants or skull defects that affect tDCS administration;
- •implanted brain medical devices, including, deep brain stimulators (DBS);
- •implanted pacemakers;
- •any electrically, magnetically, or mechanically activated implants;
- •cardiac, neural, or medication implants;
- •vascular clips or other electrically sensitive support systems in the brain;
- •damaged skin at the sites of stimulation (the device should only be used on healthy, intact skin, as wounds may alter resistance to current);
- •skin conditions such as dermatitis, psoriasis, or eczema;
- •pregnant women;
- •diagnosis of just dysarthria;
- •Use of medications that interact with or potentially interact with tDCS or EEG effects:
- •anti-convulsants;
- •carbamazepine;
- •sulpiride;
- •pergolide;
- •lorazepam;
- •rivastigmine;
- •dextromethorphan;
- •D-cycloserine;
- •flunarizine;
- •ropinirole;
- •citalopram;
- •stimulants;
- •Additionally, non-English speakers will be excluded because not all of the screening forms, questionnaires, and tests are available in languages other than English.
研究组 & 干预措施
Sham transcranial direct current stimulation
Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
干预措施: Sham transcranial direct current stimulation (Device)
Transcranial direct current stimulation
Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds. Other Names: tDCS 1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10
干预措施: transcranial direct current stimulation (Device)
结局指标
主要结局
Treatment group differences in change from Baseline to 1-week Post-Treatment on COWAT Phonemic Fluency
时间窗: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Evaluation of treatment group differences in change on COWAT Phonemic Fluency from baseline to 1-week post-treatment. Metric: Number of Correct Items Generated
Treatment group differences in change from Baseline to 2-months Post-Treatment on COWAT Phonemic Fluency
时间窗: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-months Post-Treatment
Evaluation of treatment group differences in change on COWAT Phonemic Fluency from baseline to 2-months post-treatment. Metric: Number of Correct Items Generated
Treatment group differences in change from Baseline to 1-week Post-Treatment on Category Fluency
时间窗: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
valuation of treatment group differences in change on Category Fluency from baseline to 1-week post-treatment. Metric: Number of Correct Items Generated (minimum=0 words; no maximum)
Treatment group differences in change from Baseline to 2-months Post-Treatment on Category Fluency
时间窗: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-month Post-Treatment
Evaluation of treatment group differences in change on Category Fluency from baseline to 2-months post-treatment. Metric: Number of Correct Items Generated (minimum=0 words; no maximum)
次要结局
- Treatment group differences in change from Baseline to 1-week Post-treatment on MDS-UPDRS Part III score.(Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment)
- Treatment group differences in change from Baseline to 2-month Post-treatment on MDS-UPDRS Part III score.(Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-month Post-Treatment)
- Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rate during overt reading(Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment)
- Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rate during overt reading(Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment)
- Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rate during self-generated speech(Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment)
- Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rate during self-generated speech(Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment)
- Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rhythm during overt reading(Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment)
- Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rhythm during overt reading(Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment)
- Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rhythm during self-generated speech(Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment)
- Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rhythm during self-generated speech(Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment)
- Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Pause Time during overt reading(Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment)
- Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Pause Time during overt reading(Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment)
- Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Pause Time during self-generated speech(Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment)
- Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Pause Time during self-generated speech(Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment)
- Treatment group differences in change from Baseline to 1-week Post-treatment on Freezing of Gate during the timed up and go task(Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment)
- Treatment group differences in change from Baseline to 2-month Post-treatment on Freezing of Gate during the timed up and go task(Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-month Post-Treatment)
研究者
John Hart, Jr.
Professor
The University of Texas at Dallas